Free Trial
NYSE:TAK

Takeda Pharmaceutical (TAK) Stock Price, News & Analysis

Takeda Pharmaceutical logo
$13.82 -0.26 (-1.81%)
As of 10:08 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Takeda Pharmaceutical Stock (NYSE:TAK)

Advanced

Key Stats

Today's Range
$13.80
$13.91
50-Day Range
$14.10
$15.50
52-Week Range
$12.80
$15.69
Volume
314,335 shs
Average Volume
2.59 million shs
Market Capitalization
$43.96 billion
P/E Ratio
46.08
Dividend Yield
3.98%
Price Target
N/A
Consensus Rating
Hold

Company Overview

Takeda Pharmaceutical Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
48th Percentile Overall Score

TAK MarketRank™: 

Takeda Pharmaceutical scored higher than 48% of companies evaluated by MarketBeat, and ranked 615th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for Takeda Pharmaceutical are expected to grow by 0.61% in the coming year, from $1.64 to $1.65 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Takeda Pharmaceutical is 46.13, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 233.26.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Takeda Pharmaceutical is 46.13, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 85.88.

  • Price to Book Value per Share Ratio

    Takeda Pharmaceutical has a P/B Ratio of 0.96. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Takeda Pharmaceutical's valuation and earnings.
  • Percentage of Shares Shorted

    0.30% of the float of Takeda Pharmaceutical has been sold short.
  • Short Interest Ratio / Days to Cover

    Takeda Pharmaceutical has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Takeda Pharmaceutical has recently increased by 21.85%, indicating that investor sentiment is decreasing significantly.
  • Dividend Leadership

    Takeda Pharmaceutical is a leading dividend payer. It pays a dividend yield of 3.82%, putting its dividend yield in the top 25% of dividend-paying stocks.

  • Dividend Growth

    Takeda Pharmaceutical does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Takeda Pharmaceutical is 183.33%. Payout ratios above 75% are not desirable because they may not be sustainable.

  • Dividend Sustainability

    Based on earnings estimates, Takeda Pharmaceutical will have a dividend payout ratio of 33.33% next year. This indicates that Takeda Pharmaceutical will be able to sustain or increase its dividend.

  • Read more about Takeda Pharmaceutical's dividend.
  • Percentage of Shares Shorted

    0.30% of the float of Takeda Pharmaceutical has been sold short.
  • Short Interest Ratio / Days to Cover

    Takeda Pharmaceutical has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Takeda Pharmaceutical has recently increased by 21.85%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Takeda Pharmaceutical has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Takeda Pharmaceutical this week, compared to 5 articles on an average week.
  • Search Interest

    23 people have searched for TAK on MarketBeat in the last 30 days. This is an increase of 360% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Takeda Pharmaceutical to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Takeda Pharmaceutical insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.04% of the stock of Takeda Pharmaceutical is held by insiders.

  • Percentage Held by Institutions

    Only 9.17% of the stock of Takeda Pharmaceutical is held by institutions.

  • Read more about Takeda Pharmaceutical's insider trading history.
Receive TAK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Takeda Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TAK Stock News Headlines

How to collect cash payments from the Lone Star State
Did you know there's a way you could collect regular checks, thanks to Texas's oil wealth? We call it the Texas Royalty Plan. And already, a few savvy Americans are taking advantage.tc pixel
See More Headlines

TAK Stock Analysis - Frequently Asked Questions

Takeda Pharmaceutical's stock was trading at $13.24 at the beginning of 2025. Since then, TAK shares have increased by 4.9% and is now trading at $13.8850.

Takeda Pharmaceutical Co. (NYSE:TAK) announced its earnings results on Wednesday, July, 30th. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.47 by $0.05. The business earned $7.45 billion during the quarter, compared to analyst estimates of $7.96 billion. Takeda Pharmaceutical had a trailing twelve-month return on equity of 10.50% and a net margin of 3.20%.
Read the conference call transcript
.

The following companies are subsidiaries of Takeda Pharmaceutical: PvP Biologics, Shire, TiGenix, ARIAD Pharmaceuticals, Inviragen, LigoCyte Pharmaceuticals, Intellikine, and more.

Top institutional investors of Takeda Pharmaceutical include U.S. Capital Wealth Advisors LLC.
View institutional ownership trends
.

Shares of TAK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Takeda Pharmaceutical investors own include Johnson & Johnson (JNJ), Meta Platforms (META), Taiwan Semiconductor Manufacturing (TSM), JPMorgan Chase & Co. (JPM), Alibaba Group (BABA), NVIDIA (NVDA) and Pfizer (PFE).

Company Calendar

Last Earnings
7/30/2025
Today
10/10/2025
Next Earnings (Estimated)
10/30/2025
Fiscal Year End
3/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:TAK
CIK
1395064
Employees
47,455
Year Founded
1781

Profitability

EPS (Trailing Twelve Months)
$0.30
Trailing P/E Ratio
47.00
Forward P/E Ratio
8.60
P/E Growth
N/A
Net Income
$712.33 million
Net Margins
3.20%
Pretax Margin
3.82%
Return on Equity
10.50%
Return on Assets
5.10%

Debt

Debt-to-Equity Ratio
0.60
Current Ratio
1.16
Quick Ratio
0.59

Sales & Book Value

Annual Sales
$30.09 billion
Price / Sales
1.49
Cash Flow
$3.13 per share
Price / Cash Flow
4.50
Book Value
$14.39 per share
Price / Book
0.98

Miscellaneous

Outstanding Shares
3,181,970,000
Free Float
3,180,695,000
Market Cap
$44.87 billion
Optionable
Optionable
Beta
0.21

Social Links

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NYSE:TAK) was last updated on 10/10/2025 by MarketBeat.com Staff
From Our Partners